27th week of 2014 patent applcation highlights part 56 |
Patent application number | Title | Published |
20140187542 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE - A compound represented by the following formula (I) or a salt thereof: | 2014-07-03 |
20140187543 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM - The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) | 2014-07-03 |
20140187544 | OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF - The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): | 2014-07-03 |
20140187545 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors - PI3Kβ selective compounds having the structure | 2014-07-03 |
20140187546 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria - Cystine analogs that improve the solubility of L-cystine in urine for treatment of cystinuria and which have the structure: | 2014-07-03 |
20140187547 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS - The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer. | 2014-07-03 |
20140187548 | 6 SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS - The present invention relates to substituted imidazopyrazine compounds of general formula (I) in which R | 2014-07-03 |
20140187550 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS - A compound of formula (I): | 2014-07-03 |
20140187551 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS - Compounds of the formula (I) in which R | 2014-07-03 |
20140187552 | METHOD OF TREATMENT OF AGGRESSION - The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. | 2014-07-03 |
20140187553 | Azole Compounds as PIM Inhibitors - The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer. | 2014-07-03 |
20140187554 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR - The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as RORα, RORβ, or RORγ. Compounds of the invention can be effective modulators at concentrations ineffective to act on LXR receptors, or on other nuclear receptors, or other biological targets. Methods of modulation the RORs and methods of treating metabolic disorders, immune disorders, cancer, and CNS disorders wherein modulation of an ROR is medically indicated are also provided. | 2014-07-03 |
20140187555 | NOVEL SOFT PDE4 INHIBITORS - The present invention relates to new phosphodiesterase inhibitors, more specifically soft PDE4 inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new soft PDE4 inhibitors compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including inflammatory diseases. | 2014-07-03 |
20140187556 | ANTI-AMYLOID COMPOUNDS AND METHODS - Anti-amyloid compounds are provided along with methods of use thereof. | 2014-07-03 |
20140187557 | BENZOCYCLOHEPTANE AND BENZOXEPINE DERIVATIVES - The present invention relates to a compound of formula (I) | 2014-07-03 |
20140187558 | PREPARATION OF SITAGLIPTIN INTERMEDIATES - The invention relates to the preparation of chiral compounds, in particular to the preparation of chiral compounds which may be used as intermediates for the preparation of anti-diabetic agents, preferably sitagliptin. | 2014-07-03 |
20140187559 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR - Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases. | 2014-07-03 |
20140187560 | BROMOCRIPTINE FORMULATIONS - The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycerine control in the treatment of type 2 diabetes. | 2014-07-03 |
20140187561 | SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF - In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. | 2014-07-03 |
20140187562 | PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE - The instant invention relates to crystalline forms of MK-1775, an inhibitor of Weel kinase. Specifically, the instant invention relates to hemihydrates of MK-1775. | 2014-07-03 |
20140187563 | COMBINATION THERAPY IN TREATMENT OF ONCOLOGICAL AND FIBROTIC DISEASES - The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor. | 2014-07-03 |
20140187564 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2014-07-03 |
20140187565 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2014-07-03 |
20140187566 | PHARMACEUTICAL COMBINATION OF MEK INHIBITOR AND B-RAF INHIBITORS - A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer. | 2014-07-03 |
20140187567 | AGRICULTURAL OR HORTICULTURAL FUNGICIDE COMPOSITION AND METHOD FOR CONTROLLING PLANT PATHOGEN - A composition having a stable and high fungicidal effect against a cultivated crop infected by a plant pathogen is provided. An agricultural or horticultural fungicide composition containing, as active ingredients, (a) fluazinam or its salt and (b) a strobilurin compound or its salt is provided; in addition, a method for controlling a plant pathogen by applying the subject agricultural or horticultural fungicide composition to a plant or a soil is provided; and furthermore, a method for controlling a plant pathogen by applying (a) fluazinam or its salt and (b) a strobilurin compound or its salt to a plant or a soil is provided. | 2014-07-03 |
20140187568 | CRYSTALLINE FORMS OF BOSENTAN SALTS AND PROCESSES FOR THEIR PREPARATION - The present invention relates to crystalline forms of bosentan salts and processes for their preparation. | 2014-07-03 |
20140187569 | CRYSTALLINE FORMS OF BOSENTAN SALTS AND PROCESSES FOR THEIR PREPARATION - The present invention relates to crystalline forms of bosentan salts and processes for their preparation. | 2014-07-03 |
20140187570 | NOVEL FORMULATIONS OF PYRIMETHANIL, AND THEIR USE IN TREATMENT OF CROPS - Solutions and emulsions of pyrimethanil and essential oils, and their use in fungicidal treatment of crops. | 2014-07-03 |
20140187571 | 7,8-Cyclicmorphinan Analogs - The application is directed to compounds of Formula I-A | 2014-07-03 |
20140187573 | Substituted Morphinans and the Use Thereof - The application is directed to compounds of Formula I: | 2014-07-03 |
20140187574 | USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND XENOTRANSPLANTATION - Use of a rapamycin derivative of formula I as defined in the claims for preventing or treating vasculopathies and manifestations of xenotransplantation. | 2014-07-03 |
20140187575 | LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described. | 2014-07-03 |
20140187576 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE - 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy. | 2014-07-03 |
20140187577 | BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF THYROID AND KIDNEY CANCER SUBJECTS TO LENVATINIB COMPOUNDS - Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer. | 2014-07-03 |
20140187578 | Pharmaceutical Topical Compositions - The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream. | 2014-07-03 |
20140187579 | TIP60 INHIBITORS - This invention is in the fields of immunology and autoimmunity. More particularly it concerns pharmaceutical compositions comprising compounds which are useful agents for inhibiting the functions of TIP60 and the use of such compounds in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel diseases. | 2014-07-03 |
20140187580 | Spin Traps and Spin Labels for the Treatment of Rectal Hemorrhoids - Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the treatment of rectal hemorrhoids and rectal fissures. | 2014-07-03 |
20140187581 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS - The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. | 2014-07-03 |
20140187582 | SOLID DISPERSIONS OF AMORPHOUS PAROXETINE MESYLATE - The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient. Methods for the treatment using paroxetine mesylate in the form of a solid dispersion according to the invention are also disclosed. | 2014-07-03 |
20140187583 | Polymorph Form of 4-methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid - The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid. More particularly, the invention relates to polymorph forms (Polymorph Form I or Polymorph Form II), and to processes for the preparation of, compositions containing and to uses of, such polymorph forms. | 2014-07-03 |
20140187584 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels - Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal. | 2014-07-03 |
20140187585 | 5-HT2B RECEPTOR ANTAGONISTS - The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-HT | 2014-07-03 |
20140187586 | PYRIDYLPHENYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I): | 2014-07-03 |
20140187587 | SYNERGISTIC FUNGICIDAL MIXTURES FOR FUNGAL CONTROL IN CEREALS - A fungicidal composition containing a fungicidally effective amount of (a) the compound of Formula I, (3S,6S,7R,8R)-8-benzyl-3-(3-((isobutyryloxy)methoxy)-4-methoxypicolinamido)-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate, and (b) fluxapyroxad, provides synergistic control of selected fungi. | 2014-07-03 |
20140187588 | MACROCYCLIC PICOLINAMIDES AS FUNGICIDES - The disclosure relates to macrocyclic picolinamides of Formula (I) and to the use of these compounds as fungicides. | 2014-07-03 |
20140187589 | FUNGICIDAL COMPOSITIONS FOR CONTROLLING LEAF SPOTS IN SUGAR BEETS - A new method for the control and prevention of sugar beet leaf spot caused by | 2014-07-03 |
20140187590 | SYNERGISTIC FUNGICIDAL COMPOSITIONS - A synergistic fungicidal mixture contains a fungicidally effective amount of a compound of Formula I, (3S,6S,7R,8R)-8-benzyl-3-(3-((isobutyryloxy)methoxy)-4-methoxypicolinamido)-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl isobutyrate, and at least one triazole fungicide wherein Formula I is | 2014-07-03 |
20140187591 | SOLID FORM AND METHOD FOR PREPARING THE SAME - The disclosure provides a solid form and a method for preparing the same. The solid form consists essentially of a biodegradable copolymer and an amide-containing compound. The biodegradable copolymer is semi-crystalline due to the dipole-dipole interaction between the biodegradable copolymer and the urea. The method for preparing the above solid form includes: dissolving a biodegradable copolymer and an amide-containing compound in water at a first temperature, obtaining a solution; cooling the solution at a second temperature to form a solid mixture; and the solid mixture is subjected to a freeze-drying process at a third temperature. | 2014-07-03 |
20140187592 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND - The present invention provides a compound having excellent regulating action on blood lipid level. | 2014-07-03 |
20140187593 | DIAGNOSTIC TEST AND TREATMENT FOR A NEUROLOGICAL DISORDER - Methods and compositions relating to diagnosing and treating a VMAT-2 deficiency disease are described. Provided are methods for screening for, diagnosing or detecting a risk of developing a VMAT-2 deficiency disease comprising detecting the presence of a VMAT-2 variant in a sample of a subject, wherein the presence of the VMAT-2 variant is indicative that the subject has a VMAT-2 deficiency disease or an increased risk of developing a VMAT-2 deficiency disease compared to an individual having wild type VMAT-2. Also provided are methods of treating a VMAT-2 deficiency disease with a dopamine agonist. | 2014-07-03 |
20140187594 | DIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF LIVER, LUNG DISORDERS, DIABETIC COMPLICATIONS AND CARDIOVASCULAR DISEASES - Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis. | 2014-07-03 |
20140187595 | Methods and Compositions Comprising AMPK Activator (Metformin/Troglitazone) for the Treatment of Myotonic Dystrophy Type 1 (DM1) - The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator . | 2014-07-03 |
20140187596 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN - The present invention provides a method of treating a patient suffering from pain or other FAAH mediated conditions by administering a fatty acid amide inhibiting amount of a compound represented by the formula: wherein R | 2014-07-03 |
20140187597 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MOVEMENT DISORDERS - A pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier. | 2014-07-03 |
20140187598 | Novel Solid Forms Of Bendamustine Hydrochloride - Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use. | 2014-07-03 |
20140187599 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS - Methods of treating a disease selected from dermatomyositis, prurigo nodularis, pyoderma gangrenosum, alopecia areata, hidradenitis suppurtiva, rosacea, lichen planus, giant cell arteritis, Sjogren's syndrome, gout, chronic prostatitis, posterior uveitis, vulvodynia and interstitial cystitis in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, cyclopropyl {2-[(15)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide or a combination thereof, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate or clathrate thereof. | 2014-07-03 |
20140187600 | USE OF METABOTROPIC GLUTAMATE RECEPTORS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. | 2014-07-03 |
20140187601 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION - Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression. | 2014-07-03 |
20140187602 | Anti-Sense Oligonucleotides Targeted Against Exon 9 of IL-23R alpha Gene and Method of Using Same to Induce Exon Skipping and to Treat Inflammatory Bowel Diseases - The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23Rαgene. Exon 9 skipping of the IL23Rα gene ultimately causes specific induction of a novel soluble truncated IL-23Rα (Δ9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a Δ9 protein which inhibits IL-23R-mediated cell signaling. More particularly, Δ9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease. | 2014-07-03 |
20140187603 | MICRORNA INHIBITORS COMPRISING LOCKED NUCLEOTIDES - The invention provides chemically modified oligonucleotides capable of inhibiting the expression (e.g., abundance) of miR-208 family miRNAs, including miR-208a, miR-208b, and/or miR-499. The invention provides in some embodiments, oligonucleotides capable of inhibiting, in a specific fashion, the expression or abundance of each of miR-208a, miR-208b, and miR-499. The invention further provides pharmaceutical compositions comprising the oligonucleotides, and methods of treating patients having conditions or disorders relating to or involving a miR-208 family miRNA, such as a cardiovascular condition. In various embodiments, the oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. | 2014-07-03 |
20140187604 | THERAPEUTIC AND DIAGNOSTIC TARGET GENE IN ACUTE MYELOID LEUKEMIA - Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided. | 2014-07-03 |
20140187605 | PROTECTION AGAINST ENDOTHELIAL BARRIER DYSFUNCTION THROUGH INHIBITION OF THE TYROSINE KINASE ABL-RELATED GENE (ARG) - The invention relates to the field of endothelial barrier dysfunction, particular, the invention relates to new methods for the treatment of endothelial barrier dysfunction, such as inflammatory edema by inhibiting Abl-related gene (ARG). | 2014-07-03 |
20140187606 | TREATMENT OF FRATAXIN (FXN) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO FXN - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Frataxin (FXN), in particular, by targeting natural antisense polynucleotides of Frataxin (FXN). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FXN. | 2014-07-03 |
20140187607 | METHODS OF MODULATING COMPLIANCE OF THE TRABECULAR MESHWORK - The present invention relates to method, system, and composition for modulating the compliance of the trabecular meshwork, which may provide treatment to glaucoma. | 2014-07-03 |
20140187608 | INHIBITOR OF NEURONAL CONNECTIVITY LINKED TO SCHIZOPHRENIA SUSCEPTIBILITY AND COGNITIVE DYSFUNCTION - The present invention relates to methods and compositions for enhancing neuronal connectivity. It is based, at least in part, on the discovery of a protein, termed “Mirta22,” that inhibits the formation of structures which create connections between neurons. It is further based, in part, on the discovery that inhibiting Mirta22 activity by short hairpin RNA was able to restore these structures. Mirta22 was discovered in experiments relating to 22q11 microdeletions, which have been linked to schizophrenia. Accordingly, the present invention provides for methods of treating schizophrenia comprising administering an agent that inhibits Mirta22 activity. It may also be used in the treatment of other disorders that would benefit from enhanced neural connectivity, including learning and memory disorders. | 2014-07-03 |
20140187609 | Mutator Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer - Methods of reducing spontaneous mutation rate of a cell in a subject in need thereof by reducing endogenous levels of miR-155 are described. | 2014-07-03 |
20140187610 | Connective Tissue Growth Factor Antisense Oligonucleotides - The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression. | 2014-07-03 |
20140187611 | MITOCHONDRIAL RIBOSOMAL PROTEINS AS AGING REGULATORS - The present invention relates to methods of increasing lifespan, delaying aging, and/or preventing or treating an age-related disease or a mitochondrial disease in a subject, comprising inducing a nuclear-mitochondrial OXPHOS protein dyssynchrony, including inhibiting the mitochondrial translation machinery function, as well as methods for screening agents that are able to increase lifespan, inhibit or delay aging, and/or prevent or treat an age-related disease or disorder, or a mitochondrial disease or disorder, in a subject. | 2014-07-03 |
20140187612 | METHOD OF MODULATING INTEGRIN MEDIATED CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME - An isolated nucleic acid encodes a polypeptide for inhibiting growth of a cancer cell. The amino acid sequence defines a binding domain of a β integrin subunit for ERK2 MAP kinase, the binding domain comprising an intervening, centrally located amino acid linker sequence that links opposite terminal end amino acid sequence regions of the binding domain together and is non-essential for binding of the MAP kinase to the binding domain. The linker sequence of the binding domain is deleted such that the opposite terminal end amino acid sequence regions of the binding domain remain and are contiguous with one another. Also provided are vectors incorporating the nucleic acid and methods for prophylaxis or treatment of cancer in a mammal, comprising administering the nucleic acid for expression of the polypeptide encoded by the nucleic acid in the cancer cells of the cancer. | 2014-07-03 |
20140187613 | METHODS AND PRODUCTS FOR EXPRESSION OF MICRO RNAs - The invention relates to microRNAs, methods of producing microRNAs and methods for using microRNAs. | 2014-07-03 |
20140187614 | AMINO LIPIDS, THEIR SYNTHESIS AND USES THEREOF - The present invention provides new amino lipids and a convenient method for synthesising these compounds. These (cationic) amino lipids have good properties as transfection agents. The method is an economic versatile two step synthesis allowing the preparation of various amino lipids thus leading to the assembly of a combinatorial library of transfection agents. Moreover, the present invention provides lipid particles (liposomes) containing said amino lipids and their use for delivering bioactive agents into cells. The invention encompasses also the use of lipid particles containing the cationic amino lipids as medicament. | 2014-07-03 |
20140187615 | THERAPEUTIC POLYNUCLEOTIDES, COMPOSITIONS, AND METHODS - This disclosure describes, in one aspect, a composition that generally includes an xNA molecule comprising at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating cardiac disease. Generally, the method includes administering to a subject a composition that includes an xNA molecule having at least six nucleotides, in an amount effective to improve at least one indicator of myocyte function, and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method for evaluating the efficacy of treatment of cardiac disease. Generally, the method includes administering to a subject a composition that includes a first xNA molecule comprising a predetermined length in an amount effective to increase myocyte relaxation, then selecting a predetermined length of a second xNA molecule for at least one subsequent treatment. If treatment with the first xNA results in more myocyte relaxation than is desired, then the predetermined length of the second xNA molecule is shorter than the predetermined length of the first xNA. If, on the other hand, treatment with the first xNA results in less myocyte relaxation than is desired then the predetermined length of the second xNA molecule is longer than the predetermined length of the first xNA. | 2014-07-03 |
20140187616 | CALCIUM CHANNEL PROTEINS AND USES THEREOF - Described herein are compositions and uses thereof related to Ca | 2014-07-03 |
20140187617 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE - Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved. | 2014-07-03 |
20140187618 | COMPOSITIONS, METHODS AND KITS USING FOR INDUCING OR ENHANCING NEUROGENESIS IN CELLS AND TISSUE - Compositions, methods, and kits including extracts containing physalins and pure physalins are provided for inducing neurogenesis in cells and tissues. The extracts for example are obtained from natural sources such as a plant, for example | 2014-07-03 |
20140187619 | TREATMENTS FOR DIABETES MELLITUS AND OBESITY - Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise the step of administering an active agent directly to the small intestine in the subject. In particular, the active agent may be administered directly to the duodenum in the subject. The active agents useful in the treatments described herein include analgesic agents and, in particular, antinociceptive agents such as capsaicin, resiniferatoxin, and their analogues. | 2014-07-03 |
20140187620 | COMPOSITION COMPRISING COUMESTROL OR A BEAN EXTRACT CONTAINING COUMESTROL - The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved. | 2014-07-03 |
20140187621 | COMPOSITION COMPRISING COUMESTROL OR A BEAN EXTRACT CONTAINING COUMESTROL - The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved. | 2014-07-03 |
20140187622 | COMPOSITION COMPRISING COUMESTROL OR A BEAN EXTRACT CONTAINING COUMESTROL - The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved. | 2014-07-03 |
20140187623 | Escalating Dosing Regimen For Effecting Weight Loss And Treating Obesity - The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. | 2014-07-03 |
20140187624 | METHOD OF MANAGING CHEMOTHERAPY INDUCED ALOPECIA OR CACHEXIA OR BOTH - The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along with pharmaceutical excipients. | 2014-07-03 |
20140187625 | RODENTICIDAL COMPOUND, COMPOSITION INCLUDING SAME AND USE FOR COMBATING RODENT PESTS - A novel compound obtained from molecules of the coumarin family, which exhibits rodenticidal activity. Also, compositions which incorporate such compounds and the use thereof for combating rodent pests. | 2014-07-03 |
20140187626 | OXANORBORNADIENE DERIVATIVES AND THEIR ANTICANCER ACTIVITIES - The present invention relates to chemical entities originated from natural sources and further synthesized for therapeutic uses. More particularly, the present invention relates to norcantharidin analogues synthesized by a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects. | 2014-07-03 |
20140187627 | USES OF C15-SUBSTITUTED ANDROGRAPHOLIDE DERIVATIVES IN THE PREPARATION OF ANTI-HEPATITIS B VIRUS MEDICAMENT - Disclosed is a use of C15-substituted andrographolide derivatives in preparation of anti-hepatitis B virus medicaments. In the present invention, the HepG2.2.15 cells are used to measure the amount of the hepatitis B virus surface antigen (HBsAg) secretion in the supernatant of the culture; the duck hepatitis B virus (DHBV) is used to infect the model and the DHBV-DNA level in serum is measured, and the pathological change in hepatic tissue is observed. A number of andrographolide derivative compounds are screened, compounds having a good anti-HBV effect are preferred, which has a structure represented by general formula 1 set forth herein. Due to high anti-HBV activity and low toxicity, as well as good protection against hepatic injury, the compounds can be used as the active ingredient for preparing anti-HBV medicaments, thereby providing a new pharmaceutical way for treatment of hepatitis, and broadening the range of clinical medicines. | 2014-07-03 |
20140187628 | PALATABLE SUSPENDING VEHICLE FOR PHARMACEUTICAL INGREDIENTS - The invention relates to a liquid vehicle that can be used to create suspensions and/or solutions of liquid or powdered medications. The vehicle is thixotropic and has improved stability and rheologic characteristics. Vehicles of the invention include an aqueous medium and a suspending agent comprising a polysaccharide having at least 50% glucose repeating saccharide units and at least 90% alpha linkages. The polysaccharide can be a starch, modified starch, or glycogen. The aqueous medium and individual components of the vehicle provide a palatable and easily ingested drug preparation. The invention also provides a vehicle containing an aqueous medium, suspending agent comprising a polysaccharide having at least 50% glucose repeating saccharide units and at least 90% alpha linkages, buffer, and artificial sweetener, the combined suspending vehicle having a pH of about 3 to about 10 and an osmolality of 300 mOmsol or less. | 2014-07-03 |
20140187629 | Use of Bethanechol for Treatment of Xerostomia - A formulation for topical administration, comprises bethanechol and a penetration enhancer. The formulation is preferably used by being maintained in the buccal cavity for a period of time prior to being swallowed. | 2014-07-03 |
20140187630 | NOVEL COMPOUND AND MEDICAL USE THEREOF - Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa. | 2014-07-03 |
20140187631 | METHODS FOR TREATING BRAIN INJURY - The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). | 2014-07-03 |
20140187632 | LIPID COMPOSITIONS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS AND THE PROMOTION OF INTESTINAL DEVELOPMENT AND MATURATION - The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation. | 2014-07-03 |
20140187633 | METHODS OF TREATING OR PREVENTING NONALCOHOLIC STEATOHEPATITIS AND/OR PRIMARY BILIARY CIRRHOSIS - In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2014-07-03 |
20140187634 | CURE FOR EDEMA OF THE FOOT AND ANKLE - The inventive subject matter relates to a method for treating Edema of the Foot and Ankle Edema is a medical condition characterized by swelling and discoloration caused by excess fluid trapped in the body tissues. Administration of Extra Virgin Olive Oil composition provides therapeutic results when applied to the affected area. | 2014-07-03 |
20140187635 | DICLOFENAC COMPOSITIONS - The present invention relates a composition comprising Diclofenac and salts thereof wherein Diclofenac or its salts are present in an amount of 25-200 mg. The composition is suitable for the parenteral administration through intramuscular, intravenous route; also for oral, dermal, subcutaneous, cutaneous, nasal, ocular drops, as rectal suppository, vaginal pessaries, intra-articular, and otic delivery. The invention also provides compositions comprising a combination of Diclofenac and other drugs. The invention further provides a method for preparing said composition. | 2014-07-03 |
20140187636 | CRYSTALLINE FORMS OF BIMATOPROST ACID, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The invention provides new crystalline forms of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid. This compound is commonly referred to as “bimatoprost acid.” The novel crystalline forms are designated forms I, II, and III. The invention crystalline forms are useful for solid ocular implant formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. In addition, invention crystalline forms are useful for solid or semisolid dosage formulations used to treat ocular hypertension. | 2014-07-03 |
20140187637 | TROMETHAMINE SALT OF BIMATOPROST ACID IN CRYSTALLINE FORM, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The present invention provides tromethamine salt of 7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” The invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension. | 2014-07-03 |
20140187638 | PHENYLBUTYRATE IN RECTAL FORM FOR THE TREATMENT OF A MOTOR NEURON DISEASE OR A METABOLIC DISEASE - The present invention relates to rectal administration of phenylbutyrate for treating a motor neuron disease, such as, for example, spinal muscular atrophy or a metabolic disease such as, for example, an urea cycle disorder, related methods and compositions. | 2014-07-03 |
20140187639 | Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof - Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (PIP3) and pleckstrin homology (PH) domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward particular PH domains. The small molecule inhibitors of the invention can be used alone or together with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or other cancer medicament to treat cancer. Small molecule inhibitors of the invention act synergistically in combination with TRAIL and with other Akt inhibitors in treating cancer. Pharmaceutical compositions and methods for treating cancer are provided. | 2014-07-03 |
20140187640 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS - Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione. | 2014-07-03 |
20140187641 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF - The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia. | 2014-07-03 |
20140187642 | TOPICAL TREATMENT FOR CHEMOTHERAPY INDUCED EYELASH LOSS OR HYPOTRICHOSIS USING PROSTAMIDE F2 ALPHA AGONISTS - The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment. | 2014-07-03 |
20140187643 | Method of Treatment with Anti-Inflammatory and Analgesic Compounds Which are GI-, Renal-, and Platelet-Sparing - Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase. | 2014-07-03 |